drugset / Trial / NCT02151253

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

NCT02151253

Phase 2/3 Completed 81 enrolled Duke University
RandomizedCrossoverTriple-blindTreatment

Summary

The objective of the study is to evaluate armodafinil as a wakefulness-promoting therapy as a means of improving residual daytime sleepiness in patients with treated nocturia.

Timeline

Start
2011-05
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Armodafinil Small molecule 50 mg Oral
Subject Armodafinil Small molecule 150 mg Oral
Subject Armodafinil Small molecule 250 mg Oral

Indications